CN112028976A - 2019 novel coronavirus spike protein receptor binding domain protein and application - Google Patents
2019 novel coronavirus spike protein receptor binding domain protein and application Download PDFInfo
- Publication number
- CN112028976A CN112028976A CN202010776273.0A CN202010776273A CN112028976A CN 112028976 A CN112028976 A CN 112028976A CN 202010776273 A CN202010776273 A CN 202010776273A CN 112028976 A CN112028976 A CN 112028976A
- Authority
- CN
- China
- Prior art keywords
- protein
- novel coronavirus
- receptor binding
- binding domain
- coronavirus spike
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
- G01N33/54346—Nanoparticles
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/558—Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/165—Coronaviridae, e.g. avian infectious bronchitis virus
Abstract
The invention discloses a 2019 novel coronavirus spike protein receptor binding domain protein and application thereof. The amino acid sequence of the receptor binding domain protein is shown as SEQ ID NO. 1. The invention also discloses application of the 2019 novel coronavirus spike protein receptor binding domain protein in a 2019 novel coronavirus diagnostic reagent, a virus antigen and a detection kit. The active protein provided by the invention can be combined with an antibody aiming at the epitope, and can be widely used in the fields of diagnostic reagents such as chemiluminescence, colloidal gold and the like. The colloidal gold detection reagent strip provided by the technical scheme of the invention has the characteristics of strong specificity and high sensitivity. The invention can quickly obtain the required antigen in the face of outburst epidemic situation, and prepare sufficient antigen in a week with low cost for research and development of diagnostic reagents.
Description
Technical Field
The invention relates to the field of biotechnology detection, and particularly relates to a 2019 novel coronavirus spike protein receptor binding domain protein and application thereof.
Background
Pneumonia infected by the novel coronavirus COVID-19 is mainly manifested by fever, hypodynamia, dry cough and the like, and a few patients are accompanied by upper respiratory tract and digestive tract symptoms such as nasal obstruction, watery nasal discharge, diarrhea and the like. Severe cases often develop dyspnea after one week, and severe cases rapidly progress to acute respiratory distress syndrome, septic shock, uncorrectable metabolic acidosis, and hemorrhagic coagulation dysfunction. The novel coronavirus COVID-19 has no specific medicine so far. Some cases report more clinical practice to prove the effect of the therapeutic drug, and the development of related vaccines is under development, but the time is needed for clinical application. The urgent need is to study effective diagnostic reagents as soon as possible, diagnose early, isolate early, cut off the transmission path, and control the spread of epidemic.
The detection method has high technical requirement, false negative easily occurs, a specimen needs special treatment, professional instruments and equipment such as a PCR (polymerase chain reaction) amplification instrument and gel electrophoresis are required, the detection time of the novel coronavirus is long, and a detection result needs to be operated and judged by professional technicians, so that the method cannot be applied to early primary screening of communities, primary hospitals, airports, customs, even families and other primary bases.
Therefore, a diagnostic reagent for detecting the novel coronavirus COVID-19, which is earlier, more accurate, faster and more effective, is needed to perform early differential diagnosis, and the rapid diagnostic reagent is in great demand.
The core raw material of the antibody detection rapid diagnostic reagent is an antigen, and the 2019 novel coronavirus spike protein receptor binding domain is a good target molecule.
Disclosure of Invention
In order to overcome the defects of the prior art, the invention aims to provide a 2019 novel coronavirus spike protein receptor binding domain protein and application thereof.
The technical scheme provided by the invention is as follows:
according to a first aspect of the present invention, there is provided a 2019 novel coronavirus spike protein receptor binding domain protein, the amino acid sequence of which is shown in SEQ ID No. 1.
According to a second aspect of the present invention, there is provided a method for producing a 2019 novel coronavirus spike protein receptor binding domain protein, the method comprising the steps of:
s1 predicts: predicting the amino acid sequence of the receptor binding domain of said protein;
s2 expresses: expressing the protein in a mode of expressing the inclusion body of the escherichia coli;
s3 purification: purifying the protein by a hybrid protein washing and affinity method under a denaturation condition to obtain a target protein;
s4 renaturation: in renaturation solution with disulfide bond redox couple, using dilution method to make renaturation of said target protein;
s5 purification: and further purifying the renatured target protein by an ion column and a molecular sieve, and removing foreign proteins to obtain the purified 2019 novel coronavirus spike protein receptor binding domain protein.
Further, in step S3, the hetero protein washing includes two-step washing: the first step is as follows: washing with a solution of 10 mmol/l tris (hydroxymethyl) aminomethane hydrochloride, 150 mmol/l sodium chloride, pH 7.4, 1% triton; and a second step: washing was carried out using a solution of 10 mmol/l tris (hydroxymethyl) aminomethane hydrochloride, 150 mmol/l sodium chloride, pH 7.4.
Further, the expression of the escherichia coli inclusion body comprises gene synthesis for escherichia coli codon optimization, escherichia coli transformation and expression, escherichia coli bacterium breaking and escherichia coli inclusion body obtaining.
Further, in step S4, the method further comprises a step of solubilizing the inclusion body of E.coli.
Further, the step of solubilizing the inclusion body of E.coli comprises: dissolving the inclusion body of the escherichia coli into 10 ml of 6-8 mol/L urea, stirring and dissolving for 2 hours by using an electromagnetic stirrer, centrifuging at 12000 r/min to remove precipitates, and using the harvested supernatant for renaturation.
Further, in step S4, the disulfide redox couple is reduced glutathione/oxidized glutathione.
Further, in step S4, the components of the renaturation solution are 10 mmol/L tris (hydroxymethyl) aminomethane hydrochloride, 150 mmol/L NaCl, pH 7.4, 5 mmol/L reductor glutathione, 0.5 mmol/L oxidized glutathione, 300-400 mmol/L arginine.
Further, in step S4, the renaturation process includes: dripping the target protein into renaturation liquid in rapid stirring at the speed of 0.5 ml/min; and placing the mixture in an environment at 4 ℃ for renaturation for 12 hours.
Further, in step S5, the purity of the target protein is greater than or equal to 90%.
According to a third aspect of the present invention, there is provided the above 2019 novel coronavirus spike protein receptor binding domain protein or the 2019 novel coronavirus spike protein receptor binding domain protein obtained by the above preparation method, which is useful as a 2019 novel coronavirus diagnostic agent.
According to a fourth aspect of the present invention, there is provided a 2019 novel coronavirus antigen comprising the 2019 novel coronavirus spike protein receptor binding domain protein or the 2019 novel coronavirus spike protein receptor binding domain protein obtained by the above-mentioned preparation method.
According to a fifth aspect of the present invention, there is provided a kit for detecting a 2019 novel coronavirus, comprising an antigen reagent containing the 2019 novel coronavirus spike protein receptor binding domain protein or the 2019 novel coronavirus spike protein receptor binding domain protein obtained by the above-mentioned preparation method.
The invention provides a 2019 novel coronavirus spike protein receptor binding domain protein, the amino acid sequence of the receptor binding domain protein is shown as SEQ ID NO.1, and the preparation method is realized by the following technical scheme: cloning 2019 a gene sequence of a novel coronavirus spike protein receptor binding region; the synthesized gene sequence is inserted into a pET21a expression vector, the sequence is optimized according to the preference of an escherichia coli codon, the expression vector is used for transforming BL21(DES), BL21(DE3) is an engineered cell, the expression vector is used for expressing a large amount of target protein in vitro, a monoclonal is selected, the cell is cultured, the target protein is expressed by induction, and the 2019 novel coronavirus spike protein receptor binding domain protein is obtained by bacteria breaking, inclusion body washing, inclusion body renaturation, ion column and molecular sieve column purification.
The technical scheme of the invention also provides an antigen containing 2019 novel coronavirus spike protein receptor binding domain protein, wherein the protein is virus-encoded surface structure protein, invades cells by binding with a receptor on the cell surface, is a target for vaccine development, is also an antigen for immune reagent antibody detection, and can be used as a diagnostic reagent raw material. The invention constructs the expression plasmid of the protein by predicting the receptor binding area of the protein, purifies and enriches the protein by utilizing a plurality of histidine tags, obtains the protein with a specific functional structural domain by an inclusion body renaturation method, can combine the active protein with an antibody aiming at the epitope, and can be widely used in the field of diagnostic reagents such as chemiluminescence, colloidal gold and the like.
2019 novel coronavirus spike protein receptor binding domain protein is used in a reagent for detecting a novel coronavirus antibody by a colloidal gold method, 2019 novel coronavirus spike protein receptor binding domain protein marked by colloidal gold is used on a gold pad of a reagent strip, and anti-human antibody marking is used as a T line.
The invention has the beneficial effects that: the invention can quickly obtain the required antigen in the face of outburst epidemic situation, and prepare sufficient antigen in a week with lower cost for research and development of diagnostic reagents.
Drawings
FIG. 1 is a flow chart of a method of making an exemplary embodiment of the present invention;
FIG. 2 is a flow chart of a method of making an exemplary embodiment of the present invention;
FIG. 3 is a purification of 2019 novel coronavirus spike protein receptor binding domain protein by SDS-PAGE analysis;
FIG. 4 shows the test results of the colloidal gold test strip.
Detailed Description
The present invention will be described in detail with reference to examples.
According to an exemplary embodiment of the present invention, there is provided a 2019 novel coronavirus spike protein receptor binding domain protein, the amino acid sequence of which is shown in SEQ ID N0.1.
As shown in fig. 1, according to an exemplary embodiment of the present invention, there is provided a preparation method of 2019 novel coronavirus spike protein receptor binding domain protein, the preparation method comprising the steps of:
s1 predicts: predicting the amino acid sequence of the receptor binding domain of said protein;
s2 expresses: expressing the protein in a mode of expressing the inclusion body of the escherichia coli;
s3 purification: purifying the protein by a hybrid protein washing and affinity method under a denaturation condition to obtain a target protein;
s4 renaturation: in renaturation solution with disulfide bond redox couple, using dilution method to make renaturation of said target protein;
s5 purification: and further purifying the renatured target protein by an ion column and a molecular sieve, and removing impurity proteins to obtain the purified 2019 novel coronavirus spike protein receptor binding domain protein.
Further, in step S3, the hetero protein washing includes two-step washing: the first step is as follows: washing with a solution of 10 mmol/l tris (hydroxymethyl) aminomethane hydrochloride, 150 mmol/l sodium chloride, pH 7.4, 1% triton; and a second step: washing was carried out using a solution of 10 mmol/l tris (hydroxymethyl) aminomethane hydrochloride, 150 mmol/l sodium chloride, pH 7.4.
As shown in fig. 2, according to an exemplary embodiment of the present invention, there is provided a preparation method of 2019 novel coronavirus spike protein receptor binding domain protein, the preparation method comprising the steps of:
firstly, predicting a 2019 novel coronavirus spike protein receptor binding region, selecting a sequence shown as SEQ ID N0.1 in an amino acid sequence table, synthesizing a gene sequence optimized by an escherichia coli codon, and constructing an expression vector pET21 a;
transforming escherichia coli BL21(DE3) competent cells by using the expression plasmid, and screening successfully transformed cells by using antibiotics;
selecting a monoclonal, introducing the monoclonal into a few milliliters of culture medium, and growing for 10 hours to indicate glycerol bacteria so as to facilitate subsequent culture;
culturing a larger amount of cells until the optical density reaches about 0.75, adding an inducer isopropyl-beta-D-thiogalactose with the final concentration of 1 millimole/liter, inducing the expression of the target protein, and culturing at 37 ℃ for 4 hours.
Collecting cells, crushing, purifying target protein, mainly washing inclusion body, removing impurity protein, washing in two steps, including 10 mmol/L tris (hydroxymethyl) aminomethane hydrochloride, 150 mmol/L sodium chloride, pH 7.4, washing 1% triton, and washing 10 mmol/L tris (hydroxymethyl) aminomethane hydrochloride, 150 mmol/L sodium chloride, pH 7.4;
solubilization of Inclusion bodies: using 8 mol/l urea, adding 10 mmol/l dithiothreitol to open disulfide bond;
renaturation of solubilized inclusion bodies in renaturation solution: precooling renaturation liquid in an environment at 4 ℃, wherein the renaturation liquid comprises 10 mmol/L of tris (hydroxymethyl) aminomethane hydrochloride, 150 mmol/L of sodium chloride, pH 7.4, 5 mmol/L of reduced glutathione, 0.5 mmol/L of oxidized glutathione and 300-400 mmol/L of arginine, and the renaturation liquid is dripped into the renaturation liquid in rapid stirring at the speed of 0.5 ml/min; putting the mixture into an environment with the temperature of 4 ℃ for renaturation for 12 hours;
preparing a nickel column, washing and balancing the column with double distilled water and a buffer solution respectively, centrifuging the renaturation solution, passing the renaturation solution through the column at the flow rate of 1-2 ml/min, washing the hybrid protein with the buffer solution containing 20 mmol/L imidazole, and eluting with the buffer solution containing 250 mmol/L imidazole;
the ion column Q column or SP column is used for enriching the protein with successful renaturation, and comprises the following steps: the ion column was performed by dialyzing the above liquid, passing through an anion column Q, and then eluting with a solution to which 300 mmol/L sodium chloride was additionally added;
further purification of the target protein by the molecular sieve: the eluted solution was further concentrated to about 5 mg/ml, and 1-2 ml was loaded onto a Superdex 200120 ml column at a flow rate of 1 ml/min to collect the peak.
And (3) analyzing the purity and the expression quantity by SDS-PAGE running gel, wherein the purity reaches more than 90 percent, and the expression quantity of one liter can reach hundreds of milligrams. The purification of 2019 novel coronavirus spike protein receptor binding domain protein as shown in FIG. 3 was analyzed by SDS-PAGE.
According to an exemplary embodiment of the present invention, a gold-labeled antigen containing 2019 novel coronavirus spike protein receptor binding domain protein is provided. FIG. 4 shows the test results of the colloidal gold test strip. The gold-labeled antigen prepared by the 2019 novel coronavirus spike protein receptor binding domain protein has no false positive in a negative test in a capture method colloidal gold test strip test, positive tests IgM and IgG can be detected, and the color development is clear, so that the antigen has good specificity and sensitivity.
The antigen provided by the technical scheme of the invention contains 2019 novel coronavirus spike protein receptor binding domain protein which is virus-encoded surface structure protein, invades cells by being combined with receptors on the surfaces of the cells, is a target for vaccine development, is also an antigen for antibody detection of an immune reagent, and can be used as a raw material of a diagnostic reagent.
According to an exemplary embodiment of the present invention, a receptor binding domain protein of 2019 novel coronavirus spike protein receptor binding domain protein is predicted, an expression plasmid of the protein is constructed, the protein is purified and enriched by using a plurality of histidine tags, and a receptor binding domain protein with a specific function is obtained by an inclusion body renaturation method.
According to an exemplary embodiment of the present invention, there is provided a kit for detecting a 2019 novel coronavirus, including an antigen reagent including a 2019 novel coronavirus spike protein receptor binding domain protein. 2019 novel coronavirus spike protein receptor binding domain protein is used in a reagent for detecting a novel coronavirus antibody by a colloidal gold method, 2019 novel coronavirus spike protein receptor binding domain protein marked by colloidal gold is used on a gold pad of a reagent strip, and anti-human antibody streaking is used as a T line.
The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention, and it will be apparent to those skilled in the art that the embodiments of the present invention and features of the embodiments may be combined with each other to obtain a new embodiment without conflict, and various modifications and changes may be made in the present invention. Any modification, equivalent replacement, or improvement made without departing from the spirit and principle of the present invention shall fall within the protection scope of the present invention.
Sequence listing SEQ ID N0.1:
NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSP TKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNN LDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGF QPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTN。
Claims (4)
1. a 2019 novel coronavirus spike protein receptor binding domain protein, which is characterized in that the amino acid sequence of the receptor binding domain protein is shown as SEQ ID N0.1.
2. The 2019 novel coronavirus spike protein receptor binding domain protein as defined in claim 1 for use in a 2019 novel coronavirus diagnostic agent.
3. A 2019 novel coronavirus antigen comprising the 2019 novel coronavirus spike protein receptor binding domain protein of claim 1.
4. A kit for detecting a 2019 novel coronavirus, comprising an antigen reagent, wherein the antigen reagent comprises a 2019 novel coronavirus spike protein receptor binding domain protein of claim 1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010776273.0A CN112028976A (en) | 2020-08-05 | 2020-08-05 | 2019 novel coronavirus spike protein receptor binding domain protein and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010776273.0A CN112028976A (en) | 2020-08-05 | 2020-08-05 | 2019 novel coronavirus spike protein receptor binding domain protein and application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112028976A true CN112028976A (en) | 2020-12-04 |
Family
ID=73582354
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010776273.0A Pending CN112028976A (en) | 2020-08-05 | 2020-08-05 | 2019 novel coronavirus spike protein receptor binding domain protein and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112028976A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11547673B1 (en) | 2020-04-22 | 2023-01-10 | BioNTech SE | Coronavirus vaccine |
| US11878055B1 (en) | 2022-06-26 | 2024-01-23 | BioNTech SE | Coronavirus vaccine |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111285933A (en) * | 2020-03-09 | 2020-06-16 | 四川省人民医院 | Novel coronavirus antigen colloidal gold diagnostic kit |
| CN111423486A (en) * | 2020-03-31 | 2020-07-17 | 艾柏森(江苏)生物科技有限公司 | Renaturation method of new type coronavirus recombinant protein inclusion body |
| CN211148669U (en) * | 2020-01-29 | 2020-07-31 | 兰州雅华生物技术有限公司 | S-antigen-based novel coronavirus 2019-nCoV antibody rapid detection kit |
-
2020
- 2020-08-05 CN CN202010776273.0A patent/CN112028976A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN211148669U (en) * | 2020-01-29 | 2020-07-31 | 兰州雅华生物技术有限公司 | S-antigen-based novel coronavirus 2019-nCoV antibody rapid detection kit |
| CN111285933A (en) * | 2020-03-09 | 2020-06-16 | 四川省人民医院 | Novel coronavirus antigen colloidal gold diagnostic kit |
| CN111423486A (en) * | 2020-03-31 | 2020-07-17 | 艾柏森(江苏)生物科技有限公司 | Renaturation method of new type coronavirus recombinant protein inclusion body |
Non-Patent Citations (1)
| Title |
|---|
| JIANDONG HUO等: "Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2", 《NATURE STRUCTURAL & MOLECULAR BIOLOGY》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11547673B1 (en) | 2020-04-22 | 2023-01-10 | BioNTech SE | Coronavirus vaccine |
| US11925694B2 (en) | 2020-04-22 | 2024-03-12 | BioNTech SE | Coronavirus vaccine |
| US11878055B1 (en) | 2022-06-26 | 2024-01-23 | BioNTech SE | Coronavirus vaccine |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112028975A (en) | 2019 method for preparing novel coronavirus spike protein receptor binding domain protein | |
| CN112028976A (en) | 2019 novel coronavirus spike protein receptor binding domain protein and application | |
| EP2757111A1 (en) | Anti-human norovirus gii antibody | |
| WO2023078447A1 (en) | Antibody against novel coronavirus and reagent and kit for testing novel coronavirus | |
| US20210324054A1 (en) | Binding protein of ns1 protein | |
| KR20210031946A (en) | NS1 protein binding protein and application | |
| CN111253478B (en) | Mycoplasma pneumoniae antigen and preparation method and application thereof | |
| CN114276445B (en) | Rotavirus recombinant protein specific antibody, plasmid vector and method | |
| JP4589756B2 (en) | D-dimer measurement kit | |
| CA2499926A1 (en) | Antibody against von willebrand factor cleaving enzyme and assay system using the same | |
| US20210395347A1 (en) | Ns1-binding protein | |
| KR102041119B1 (en) | Reagent for assaying anti-treponema pallidum antibody | |
| CN110996986A (en) | Multi-epitope fusion protein of HCV antigen and application thereof | |
| CN110618270B (en) | Preparation method of reagent for quantitatively determining helicobacter pylori antigen in feces | |
| CN101995460B (en) | Ractopamine residual time resolution immunoassay kit and detection method thereof | |
| CN113666988A (en) | Preparation method and application of N-terminal structural domain of novel coronavirus nucleocapsid protein | |
| JPS63123395A (en) | Anti-pci monoclonal antibody | |
| CN108588096B (en) | Babesia orientalis spheroid protein gene 4 and protein coded by same | |
| CN109734790A (en) | People Agrin antigen, people's Agrin antibody assay kit and the preparation method and application thereof | |
| CN117285639B (en) | Anti-ethyl glucuronide antibody, and reagent and kit for detecting ethyl glucuronide | |
| CN114196643B (en) | Process and method for purifying TPO | |
| CN116836273B (en) | Anti-serum amyloid A antibody, reagent for detecting serum amyloid A and kit | |
| CN111879928B (en) | Porcine epidemic diarrhea virus antibody detection kit and application thereof | |
| Schofield et al. | Sequencing and affinity determination of antigen-specific B lymphocytes from peripheral blood | |
| CN116535505B (en) | Anti-erythrocyte envelope antigen antibody, reagent and kit containing same and method for trapping or separating erythrocyte |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20201204 |